Active
Spikevax
Moderna's original COVID-19 mRNA vaccine (mRNA-1273), the product that validated mRNA vaccines at global scale. Now sold as a seasonal respiratory vaccine and the company's largest historical revenue driver.
ModernaIntismeran autogene (mRNA-4157)
In Development
An individualized neoantigen cancer therapy, co-developed with Merck, that is custom-manufactured for each patient's tumor mutations and given with KEYTRUDA to train the immune system against the cancer. It is Moderna's highest-value pipeline asset.
Latest update Sep 8, 2026
01
Current status
Investigational. Phase 3 INTerpath-001 (adjuvant melanoma) met both its primary endpoint (recurrence-free survival) and key secondary endpoint (distant metastasis-free survival) in August 2026, the first positive Phase 3 result ever for an individualized mRNA neoantigen cancer therapy. As of September 8, 2026 no regulatory filing has been submitted; Moderna and Merck say they will present data at a medical meeting and engage with regulators. Phase 3 lung-cancer trials remain enrolling, across nine Phase 2/3 oncology studies.
02
Specifications2
03
More from Moderna5
- Active
mRESVIA
mRNA vaccine (mRNA-1345) against respiratory syncytial virus (RSV) - the first mRNA vaccine approved for a disease other than COVID-19, and a key pillar of Moderna's expanding respiratory franchise.
- Active
mFlusiva
Moderna's standalone mRNA seasonal influenza vaccine (mRNA-1010), the fourth product in its respiratory franchise alongside Spikevax, mRESVIA, and mCOMBRIAX.
- Active
mCOMBRIAX
Moderna's combination COVID-19 and influenza vaccine (mRNA-1083), the world's first authorized flu-plus-COVID combination vaccine, delivered as a single shot.
04
More in Biotech
In DevelopmentAurora Powerhouse
Oklo
Oklo's fast-fission powerhouse product line is designed for build-own-operate deployment, targeting customers that want firm clean power in a smaller footprint than traditional large reactors.
In DevelopmentFuel Recycling
Oklo
Oklo is developing an advanced fuel center to recycle used nuclear fuel and fabricate metal fuel for Aurora and other fast-reactor applications.
Early CommercializationAtomic Alchemy Isotope Platform
Oklo
Oklo's isotope business combines the Idaho Radiochemistry Laboratory, a planned pilot reactor in Texas, and a future multi-reactor foundry to supply critical medical, industrial, research, defense, and space isotopes.
In DevelopmentNatrium
TerraPower
Sodium-cooled fast reactor with integrated molten salt energy storage, enabling flexible output from 345 MWe to 500 MWe peak.